Overview

A Study of Stereotactic Body Radiation Therapy and Radium (Ra-223) Dichloride in Prostate Cancer That Has Spread to the Bones

Status:
Recruiting
Trial end date:
2024-11-12
Target enrollment:
Participant gender:
Summary
Participants will either receive treatment with standard SBRT and the study drug Radium (Ra-223) dichloride, or standard SBRT alone.
Phase:
Phase 2
Details
Lead Sponsor:
Memorial Sloan Kettering Cancer Center